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Abstract 
Brain irradiation is commonly used for many primary brain malignancies. After 
radiotherapy, the potential for the development of radiation-induced 
vasculopathy exists and should be kept in mind. Craniopharyngioma is one rare 
slowly developing, usually benign tumor. In the majority of cases, such tumors 
grow above the anterior upper lip of pituitary gland and are located mainly on 
Sella Turcica or on side sella areas. Macroscopically, they seem like big globe 
tumors with the white or red-blooded surface. Histologically, have ascertained 
two types, adamantinomatous and papillary type (though they have ascertained 
and mixed types). However, independently of their main type, they usually have 
cystic form. The size of craniopharyngioma is between 2 to 4 cm. Strike 0,12-
2/100.000 people a year, 30 to 50% of all cases presenting during childhood and 
adolescence and they constitute the 2-5% of all brain tumors. The peak 
incidence rates have been shown in children of ages 5 to 14 years and adults of 
ages 50 to 74 years.  The study below presents one case of post-radiation 
vasculopathy of the brain arteries of the patient who received radiation therapy 
to the brain as part of his craniopharingioma management. It will be 
underscored the significance of this patient condition and also will be described 
possible routes to prevent the occurrence of vasculopathy. 
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Introduction  
Craniopharyngioma is a rare benign 
brain tumor arising along the 
craniopharyngeal duct and usually 
diagnosed during childhood or adult 
life with low histological grade 
(Hermann et al. 2014, Karavitaki et al. 
2006). A plethora of patients are 
treated with both surgery and/or 
radiotherapy [Lo et al. 2016]. 
Radiotherapy is one of the primary 
treatments of brain tumors (Kralik et 
al. 2017). Although survival rates after 
removal of craniopharyngioma is 80-
90% at 10 years by radioactive 
radiation (Habrand et al. 1999, Lo et 
al. 2014, Hetelekidis et al. 1993), 
patients with craniopharyngioma suffer 
potential adverse effects including 
hypopituitarism, visual problems, 
seizures, neurocognitive impairment, 
mood disorders (Varlotto et al. 2002, 
Laffond et al. 2012, Boop et al. 2012, 
Shiminski-Maher et al. 1990, 
Sterkenburg et al. 2015) and also 
radiation necrosis, atrophy, gliosis, 
telangiectasia, cavernous 
malformations (Wang et al. 2014). 
Cerebrovascular vasculopathy is also a 
potential adverse effect of cranial 
radiotherapy (Liu et al. 2009, Ayuk et 
al. 2012, Mueller et al. 2013, Ullrich et 
al. 2005). In the study of Brant-
Zawadzki et al. was reported, when 
radiation-induced cerebrovascular 
vasculopathy occurs, histologically 
accompanying by the presence of 
subintimal foam cells and myointimal 
proliferation, fibrous thickening and 
hyalinization of the subintima, 
thickening of the elastica, fibrous 
thickening of the adventitia, and loose 
connective tissue thickening occluding 
the lumen (Brant-Zawadzki et al. 
1980). It should also be noted that 
patients with a predisposition to insulin 
resistance, glucose intolerance, 
dyslipidemia, and hypertension have 
an increased risk of vasculopathy after 
radiotherapy of craniopharyngioma 
(Srinivasan et al. 2004).  In the 
proposed study we report a case of a 
vasculopathy caused by radiotherapy 
of craniopharyngioma to continue for 3 
years because the area of 
craniopharyngioma’s location is not 
surgically removable area. The 
craniopharyngioma detected for the 
first time by magnetic resonance 
imaging (MRI) due to often and 
intense headaches. The result of 
angiopathy became the automatic 
rupture of the vessels with the 
subsequent formation of subarachnoid 
bleeding and hematoma which together 
with the existing craniopharyngioma 
due to the pressure exerted on the basic 
brain structures, caused death because 
of cardiopulmonary failure. Thus, 
although radiotherapy carries a large 
number of degenerative changes in the 
surrounding highly functional areas, 
this method of treatment remains the 
best when it is not possible to perform 
a surgical intervention (Caldarelli et al. 
2005). 
 
Methods 
The male patient was taken to the 
hospital with the following symptoms - 
often and intense headaches. 
Hereinafter was diagnosed with the 
craniopharyngioma in the pituitary 
area after the execution of the MRI. 
The maximum size of the 
craniopharyngioma was 2 cm. 
Subsequently, the patient was treated 
with laser for 3 years, because the 
craniopharyngioma was located in was 
not surgically removable area. The 
irradiation of the area caused 
postoperative metacentric 
vasculopathy and in combination that 
the patient suffered from hypertension, 
occurred the automatical rupture of the 
vessels and the formation of 
subarachnoid bleeding and hematoma. 
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Probably the bleeding started 
intraparenchymally, in the area where 
the tumor was previously located. Mild 
brain edema also was reported. 
Regarding the symptomatology, the 
patient was observed visual disorders 
and breathlessness, for around 3-4 days 
before his death. Eventually, the cause 
of death was a cardiopulmonary failure 
due to pressure on the basic brain 
structures. 
 
Results  
Notwithstanding craniopharyngioma 
was treated with radiation therapy, 
three years after it initiated, the patient 
developed vasculopathy, which led to 
the rupture of cerebral vessels with the 
subsequent bleeding. It is worth noting 
that vasculopathy rarely occurs as a 
consequence of radiation therapy. Only 
in two studies out of 7, on the basis of 
which a review of Bradley et al. was 
performed, vasculopathy was reported 
as a consequence of radiotherapy 
(Bradley et al. 2014). In the study of 
Luu et al. 16 patients who have treated 
craniopharyngioma with radiation 
therapy, only two developed 
vasculopathy which did not lead to 
death (Luu et al. 2006). Also in the 
study of Bishop et al. only two of 19 
patients developed vasculopathy, 
which was not fatal (Bishop et al. 
2013). Thus, death from vasculopathy 
was not reported in any case. 
Nevertheless, in the proposed study we 
report the vasculopathy is considered 
the primary cause of death, since 
subarachnoidal bleeding is a 
consequence of vasculopathy, and was 
caused by an additional pathology, 
hypertension, related to an increased 
risk of subarachnoidal bleeding (Feigin 
et al. 2005). Subarachnadial bleeding, 
in turn, caused secondary 
consequences, such as pressure on the 
surrounding brain structures 
responsible for the basic functions of 
the body, which was the ultimate cause 
of death. 
Discussion  
Craniopharyngioma is a tumor in the 
pituitary region with an incidence rate 
of 1.34 in all ages per 1 million 
(Nielsen et al. 2011). It represents 
approximately 2.5 – 3% of brain 
tumors in adults in the United States 
(Bunin et al. 1998; Karavitaki et al. 
2006). Notwithstanding it is 
histologically benign, its infiltrative 
behavior affects the pituitary axis, the 
visual pathways, and other relevant 
vascular and neural structures and 
often has a long-term effects sequelae 
after surgical removal, that obstructs 
total removal of disease. Optimal 
therapeutic management of 
craniopharyngioma continues to be 
debated (Pietro Mortini et al. 2011). 
There are no commonly accepted 
guidelines or a clear consensus for best 
treatment's type of craniopharyngiomas 
in adults, although in some reports 
published have recommended radiation 
therapy after subtotal or partial 
removal of craniopharyngiomas, at 
least for adults (De Vile et al. 1996; 
Duff et al. 2000). Nonetheless, optimal 
treatment's type should always be 
determined considering, for example, 
the patient’s symptoms, age, tumor 
localization, and extension. 
Since the discovery of the effects of 
radiotherapy on cranial tumors, many 
investigations have been conducted 
with the patient's observation after 
treatment and possible outcomes, such 
as a vasculopathy. The syndrome of 
radiation-induced intracranial 
vasculopathy is accepted in the 
community of radio oncology. 
Vasculopathy is frequently not 
comprised of informed consents as a 
complication of radiotherapy to the 
brain for pediatric and young adult 
patients. 
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The first cases, published in the 
international bibliography, were 
reported in 1967 by Darmody et al. 
(Darmody et al. 1967) after brain 
irradiation for pituitary adenoma and 
Lee and Hodes (Lee and Hodes 1967) 
in consequence of irradiation for optic 
glioma. Ishibashi et al. reported a case 
of a 64-year-old woman, who had a 
chromophobe pituitary adenoma 
removed and followed by radiotherapy, 
six years after treatment she developed 
vasculopathy (Ishibashi et al. 1982). 
Turel et al., who evaluated 
retrospectively 42 adults’ patients of 
which 34 had undergone radiation 
therapy, reported vasculopathy in one 
case with worsening of vision, as 
evidenced by MRI (Turel et al. 2016). 
Sawamura et al. reported vasculopathy 
of large intracranial arteries in 3 of 111 
patients after irradiation over the para 
sellar region; two-thirds of these 
patients had a stroke, 2 and 14 years 
after irradiation, and one-third 
developed a huge dural arteriovenous 
malformation 11 years after 
(Sawamura et al. 1998). 
Although there are many clinical cases 
of radiation-induced vasculopathy in 
the published literature, only a small 
part of them refers to the description of 
adult patients. The causes of 
vasculopathy can be implicated with 
various types of radiation such as 
Gamma Knife, colloidal gold 
intracystic instillation, fractionated 
external beam radiation therapy, and 
stereotactic radiosurgery. Moreover, it 
is obvious that any part of the brain 
may be exposed to the risk of 
developing vasculopathy. The time 
interval from the moment of radiation 
therapy until the onset of symptoms of 
vasculopathy ranges from 2 to 25 
years. But in most cases, vasculopathy 
is manifested in the first 10 years 
(Aoki et al. 2002). Notwithstanding 
this disease has a long latency period, 
the symptoms that manifest themselves 
are frequently acute. The course of the 
disease may have periodic 
improvements, but in general, it has a 
deteriorating pattern. Patients in many 
cases present stroke-like symptoms 
(Peñagarícano et al. 2004). Increased 
development of vasculopathy leads to 
systemic disorders that may involve 
motor impairment, sensory loss, ataxia, 
speech difficulty, or decreased 
cognitive ability. Due to the constantly 
recurring ischemic episodes caused by 
vasculopathy, there is a gradual 
deterioration in the functional status of 
patients. 
In patients with vasculopathy, 
transdural collateral vascularization 
may be the main source of blood 
supply to the part of the brain where 
there is no damage to the brain vessels. 
So it is crucial to preserve this vascular 
anastomosis during the operation. 
Magnetic resonance imaging of 
patients suffering from vasculopathy, 
prior to the use of radiation therapy, 
can help in determining the sites of 
stenosis and obstruction in the blood 
vessels of the brain. The MRI pattern 
seen after the use of radiation therapy 
is similar to that expressed in vascular 
atherosclerosis. Thickening of the 
endothelium of the vascular walls of 
the brain can be observed on MRI and 
several years after the occurrence of 
occlusion or stenosis. In our case, the 
patient was treated only with radiation 
therapy. By dint of multimodal 
planning of radiotherapy with visual 
control, it is crucial to exclude large 
arteries of the brain that do not need 
treatment and can be injured. In 
contrast, MR studies and MR 
angiography can clearly define the 
boundaries of large arteries. Thus far, 
there are no proven methods that can 
reduce the possibility of vasculopathy 
after radiotherapy. The adjustment of 
time-dose-fractionation and volume 
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does not allow to avoid the occurrence 
of this complication. The 
administration of corticosteroids prior 
to and throughout the course of 
radiation therapy was proposed as a 
possible prevention option, but its 
effectiveness remains unproven. It has 
been reported that baby aspirin 
treatment is beneficial and may reverse 
some of the symptoms. Prevention by 
delaying radiation therapy in young 
patients for as long as possible remains 
the best method of treatment. If 
treatment still needs to be done, then to 
prevent radiation-induced 
vasculopathy, modern planning and 
delivery techniques with conformal 
coverage and conformal avoidance can 
be used as the preventive method. 
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